Comprehensive Cancer Center Vienna, Department of Medicine I, Medical University of Vienna, Austria.
Hamostaseologie. 2012;32(2):105-14. doi: 10.5482/ha-1163. Epub 2011 Aug 12.
Etiological concepts on cancer development, malignant growth and tumour propagation have undergone a revolutionary development during recent years: Among other aspects, the discovery of angiogenesis - the growth of new blood vessels from pre-existing vasculature - as a key element in the pathogenesis of malignancy has opened an abundance of biologic insights and subsequent therapeutic options, which have led to improved prognosis in many cancers including those originating from colon, lung, breast and kidney. Thereby, targeting the major pro-angiogenic stimulus vascular endothelial growth factor (VEGF) became the focus for therapeutic interventions. However, the use of VEGF-targeting drugs has been shown to be of limited efficacy, which might lie in the fact that tumor angiogenesis is mediated by a variety of different subcellular systems. This review focuses on the basic mechanisms involved in angiogenesis, which potentially represent novel targets for pharmacological agents in the treatment of malignancies.
近年来，癌症发展、恶性生长和肿瘤传播的病因学概念发生了革命性的发展：在其他方面，血管生成——即从预先存在的脉管系统中生长新血管——的发现作为恶性肿瘤发病机制的关键因素，开辟了大量的生物学见解和随后的治疗选择，这导致包括结肠癌、肺癌、乳腺癌和肾癌在内的许多癌症的预后得到改善。因此，针对主要的促血管生成刺激因子血管内皮生长因子 (VEGF) 成为治疗干预的焦点。然而，已经表明，使用 VEGF 靶向药物的疗效有限，这可能在于肿瘤血管生成是由多种不同的亚细胞系统介导的。这篇综述重点介绍了血管生成中涉及的基本机制，这些机制可能代表治疗恶性肿瘤的药理学药物的新靶点。
